Results 11 to 20 of about 7,917 (182)
Vigabatrin-Induced Visual Field Defects
A drug surveillance database at Hoechst Marion Roussel, manufacturers of vigabatrin, identified 92 cases of symptomatic visual field defects associated with vigabatrin (usually as add-on therapy) between 1990 and 1997.
J Gordon Millichap
doaj +2 more sources
Vigabatrin-Associated Visual Field Defects
The prevalence, risk factors, and long-term outcome of vigabatrin-associated visual field defects were examined in 60 adult patients with partial epilepsy treated with vigabatrin for 7 months to 14 years at the University of Kuopio Hospital, Finland.
J Gordon Millichap
doaj +2 more sources
Towards a Synthesis of Vigabatrin Using Glycal Chemistry
Application of the Ferrier rearrangement led to a novel carbohydrate based synthetic route to 4-aminohexenoic acid viz. (R) and (S)-vigabatrin. The potential of D- glucose or D-galactose as the chiral starting materials for the synthesis of (R) and (S ...
I. Aidhen, J. Aidhen, S. Boga
doaj +2 more sources
Vigabatrin-Associated “Acute Encephalopathy”
A 6-month-old girl with Alexander disease and hydrocephalus, treated at Children’s Hospital, Tubingen, Germany, developed acute encephalopathy within 3 days of starting vigabatrin (VGB).
J Gordon Millichap
doaj +2 more sources
A 5.5-month-old female infant with tuberous sclerosis complex presented with infantile spasms and was treated with vigabatrin. As her condition did not improve, she was given adrenocorticotropic hormone (ACTH) intramuscularly which stopped the spasms and
Eleni Klinaki +6 more
doaj +4 more sources
Vigabatrin Intractable Epilepsy
The relationship between vigabatrin dosage and plasma concentrations, platelet GABA-transaminase inhibition and seizure reduction in 16 children with refractory epilepsy was studied at the University of Cantabria, Santander, Spain.
J Gordon Millichap
doaj +2 more sources
Vigabatrin Trials and Dose Recommendations
Major, well-controlled trials of Vigabatrin for infantile spasms in Europe, Canada, and the Unites States are reviewed, including dose recommendations.
J Gordon Millichap
doaj +2 more sources
Safety and Efficacy of Vigabatrin for the Treatment of Infantile Spasms
In 2009, vigabatrin became the first FDA approved medication for the treatment of infantile spasms in the United States. There are few well-designed prospective studies comparing the drug to placebo or other modalities used in the treatment of infantile ...
Michele A. Faulkner, Justin A. Tolman
doaj +2 more sources
Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms [PDF]
Jason T Lerner1, Noriko Salamon2, Raman Sankar1,31Departments of Pediatrics, 2Radiological Sciences, 3Neurology, David Geffen School of Medicine, University of California Los Angeles and Mattel Children’s Hospital at UCLA, Los Angeles, CA ...
Jason T Lerner +2 more
doaj +2 more sources
Vigabatrin Monotherapy for Infantile Spasms
The successful management of 21 children with infantile spasms and hypsarrhythmia using vigabatrin monotherapy is reported from the Alder Hey Children’s Hospital, Liverpool, UK.
J Gordon Millichap
doaj +2 more sources

